Alnylam's shares dip as analyst backs rival after rare disea...

Alnylam has revealed the data that forms the basis of its filings for its latest potential rare disease drug lumasiran, but shares dipped after an analyst suggested it could be outperformed

Alnylam files its third RNAi drug lumasiran in rare kidney d...

AZ adds gene silencing tech to pipeline with Silence Therape...

AstraZeneca has announced a collaboration with UK biotech Silence Therapeutics to develop gene silencing drugs for cardiovascular, renal, metabolic and respiratory diseases.

Alnylam gets CHMP backing for second gene-silencing drug Giv...

Alnylam to file rare kidney disease drug after trial win

After years where RNA interference research was in the doldrums, Alnylam is on a roll and is preparing to file a rare kidney disease drug with the FDA, after two previous approvals.

FDA approves Alnylam's second RNAi drug - with $442K annual ...

Alnylam has had a second RNA interference (RNAi) drug approved by the FDA, to treat the ultra-rare disease acute hepatic porphyria, with an ultra-high price tag to match.